These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4875711)

  • 21. Coupling of beta-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats.
    Sako Y; Grill VE
    Diabetes; 1990 Dec; 39(12):1580-3. PubMed ID: 2245882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of thiazides upon insulin secretion in vitro.
    Malaisse W; Malaisse-Legae F
    Arch Int Pharmacodyn Ther; 1968 Jan; 171(1):235-9. PubMed ID: 4868989
    [No Abstract]   [Full Text] [Related]  

  • 23. Improvement in insulin secretion in diabetes after diazoxide.
    Greenwood RH; Mahler RF; Hales CN
    Lancet; 1976 Feb; 1(7957):444-7. PubMed ID: 55717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucose metabolism and plasma insulin level during epinephrine infusion in the dog.
    Altszuler N; Steele R; Rathgeb I; De Bodo RC
    Am J Physiol; 1967 Mar; 212(3):677-82. PubMed ID: 6020543
    [No Abstract]   [Full Text] [Related]  

  • 25. Reversal of diazoxide effects by tolbutamide.
    Wales JK; Grant AM; Wolff FW
    Lancet; 1967 May; 1(7500):1137-8. PubMed ID: 4164793
    [No Abstract]   [Full Text] [Related]  

  • 26. B-cell insensitivity in vitro: reversal by diazoxide entails more than one event in stimulus-secretion coupling.
    Björklund A; Grill V
    Endocrinology; 1993 Mar; 132(3):1319-28. PubMed ID: 7679978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies on diazoxide-induced hyperglycemia: an extrapancreatic mechanism.
    Bleicher SJ; Chowdhury F; Podolsky S; Fleishman P; Goldner MG
    Ann N Y Acad Sci; 1968 Apr; 150(2):294-302. PubMed ID: 4299221
    [No Abstract]   [Full Text] [Related]  

  • 28. Galanin and epinephrine act on distinct receptors to inhibit insulin release by the same mechanisms including an increase in K+ permeability of the B-cell membrane.
    Drews G; Debuyser A; Nenquin M; Henquin JC
    Endocrinology; 1990 Mar; 126(3):1646-53. PubMed ID: 1689655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the mechanism of diazoxide-induced hyperglycemia.
    Altszuler N; Moraru E; Hampshire J
    Diabetes; 1977 Oct; 26(10):931-5. PubMed ID: 908462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacological studies of a new highly effective blood sugar decreasing sulfonamide, glibenclamide (HB 419)].
    Loubatières A; Mariani MM; Ribes G; de Malbosc H; Alric R; Chapal J
    Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1354-63. PubMed ID: 4899083
    [No Abstract]   [Full Text] [Related]  

  • 31. The hyperglycemic and antidiuretic activity of a phthalimidine analogue: 1-oxo-3-(4'-chlorophenyl)-3-hydroxyisoindoline (C3-176).
    Wales JK; Bradley P; Viktora J; Wolff FW
    Proc Soc Exp Biol Med; 1968 Jun; 128(2):581-7. PubMed ID: 5663278
    [No Abstract]   [Full Text] [Related]  

  • 32. [Mechanism of action of a hyperglycemic sulfonamide, Diazoxide].
    Loubatières A; Mariani MM; Alric R; Ribes G; De Malbosc H; Chapal J
    Ann Endocrinol (Paris); 1966; 27(6):787-94. PubMed ID: 5339929
    [No Abstract]   [Full Text] [Related]  

  • 33. New perspectives on the actions of sulphonylureas and hyperglycaemic sulphonamides on the pancreatic beta-cell.
    Flatt PR; Shibier O; Szecowka J; Berggren PO
    Diabete Metab; 1994; 20(2):157-62. PubMed ID: 7805953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diazoxide and D600 inhibition of insulin release. Distinct mechanisms explain the specificity for different stimuli.
    Henquin JC; Charles S; Nenquin M; Mathot F; Tamagawa T
    Diabetes; 1982 Sep; 31(9):776-83. PubMed ID: 6131003
    [No Abstract]   [Full Text] [Related]  

  • 35. Diazoxide-induced long-term hyperglycemia. II. Slackening of proinsulin conversion.
    Valverde I; Alarcon C; Rovira A; Malaisse-Lagae F; Malaisse WJ
    Diabetes Res; 1989 Feb; 10(2):59-62. PubMed ID: 2663320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The morphological substrate of the inhibition of insulin secretion by diazoxide.
    Creutzfeldt W; Creutzfeldt C; Frerichs H; Perings E; Sicklinger K
    Horm Metab Res; 1969 Mar; 1(2):53-64. PubMed ID: 4334867
    [No Abstract]   [Full Text] [Related]  

  • 37. Metabolic, cationic and secretory response to D-glucose in depolarized and Ca(2+)-deprived rat islets exposed to diazoxide.
    Lebrun P; Antoine MH; Nguyen QA; Picton S; Malaisse WJ
    Cell Calcium; 2000 Apr; 27(4):213-22. PubMed ID: 10858667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets.
    Song SH; Rhodes CJ; Veldhuis JD; Butler PC
    Endocrinology; 2003 Aug; 144(8):3399-405. PubMed ID: 12865318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Physiological and pharmacological aspects of the central role of the pancreas in the mode of action of hypoglycemic sulfonamides].
    Loubatières A
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():216-55. PubMed ID: 4906020
    [No Abstract]   [Full Text] [Related]  

  • 40. A morphological study on the mechanism of diazoxide-hyperglycemia (clinical and experimental investigation).
    Yoshinaga T
    Endokrinologie; 1969; 54(5):410-22. PubMed ID: 4188182
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.